SrasV1, PubMed, Curation, bibRecord, 000207

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.

Identifieur interne : 000207 ( PubMed/Curation ); précédent : 000206; suivant : 000208

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.

Auteurs : Boscolli Barbosa Pereira [Brésil]

Source :

Journal of toxicology and environmental health. Part B, Critical reviews [ 1521-6950 ] ; 2020.

RBID : pubmed:32281481

Abstract

As a result of the 2019 coronavirus disease pandemic (COVID-19), there has been an urgent worldwide demand for treatments. Due to factors such as history of prescription for other infectious diseases, availability, and relatively low cost, the use of chloroquine (CQ) and hydroxychloroquine (HCQ) has been tested in vivo and in vitro for the ability to inhibit the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, even though investigators noted the therapeutic potential of these drugs, it is important to consider the toxicological risks and necessary care for rational use of CQ and HCQ. This study provides information on the main toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ but mainly HCQ, which is a less toxic derivative than CQ, and was shown to produce better results in inhibiting proliferation of SARS-CoV-2 based upon preliminary tests.

DOI: 10.1080/10937404.2020.1752340
PubMed: 32281481

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000207

Links to Exploration step

pubmed:32281481

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.</title>
<author><name sortKey="Pereira, Boscolli Barbosa" sort="Pereira, Boscolli Barbosa" uniqKey="Pereira B" first="Boscolli Barbosa" last="Pereira">Boscolli Barbosa Pereira</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Geography, Department of Environmental Health, Federal University of Uberlândia, Santa Mônica Campus, Uberlândia, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Institute of Geography, Department of Environmental Health, Federal University of Uberlândia, Santa Mônica Campus, Uberlândia</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32281481</idno>
<idno type="pmid">32281481</idno>
<idno type="doi">10.1080/10937404.2020.1752340</idno>
<idno type="wicri:Area/PubMed/Corpus">000207</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000207</idno>
<idno type="wicri:Area/PubMed/Curation">000207</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000207</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.</title>
<author><name sortKey="Pereira, Boscolli Barbosa" sort="Pereira, Boscolli Barbosa" uniqKey="Pereira B" first="Boscolli Barbosa" last="Pereira">Boscolli Barbosa Pereira</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Geography, Department of Environmental Health, Federal University of Uberlândia, Santa Mônica Campus, Uberlândia, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Institute of Geography, Department of Environmental Health, Federal University of Uberlândia, Santa Mônica Campus, Uberlândia</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of toxicology and environmental health. Part B, Critical reviews</title>
<idno type="eISSN">1521-6950</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As a result of the 2019 coronavirus disease pandemic (COVID-19), there has been an urgent worldwide demand for treatments. Due to factors such as history of prescription for other infectious diseases, availability, and relatively low cost, the use of chloroquine (CQ) and hydroxychloroquine (HCQ) has been tested <i>in vivo</i>
 and <i>in vitro</i>
 for the ability to inhibit the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, even though investigators noted the therapeutic potential of these drugs, it is important to consider the toxicological risks and necessary care for rational use of CQ and HCQ. This study provides information on the main toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ but mainly HCQ, which is a less toxic derivative than CQ, and was shown to produce better results in inhibiting proliferation of SARS-CoV-2 based upon preliminary tests.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32281481</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-6950</ISSN>
<JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>Journal of toxicology and environmental health. Part B, Critical reviews</Title>
<ISOAbbreviation>J Toxicol Environ Health B Crit Rev</ISOAbbreviation>
</Journal>
<ArticleTitle>Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.</ArticleTitle>
<Pagination><MedlinePgn>1-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1080/10937404.2020.1752340</ELocationID>
<Abstract><AbstractText>As a result of the 2019 coronavirus disease pandemic (COVID-19), there has been an urgent worldwide demand for treatments. Due to factors such as history of prescription for other infectious diseases, availability, and relatively low cost, the use of chloroquine (CQ) and hydroxychloroquine (HCQ) has been tested <i>in vivo</i>
 and <i>in vitro</i>
 for the ability to inhibit the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, even though investigators noted the therapeutic potential of these drugs, it is important to consider the toxicological risks and necessary care for rational use of CQ and HCQ. This study provides information on the main toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ but mainly HCQ, which is a less toxic derivative than CQ, and was shown to produce better results in inhibiting proliferation of SARS-CoV-2 based upon preliminary tests.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pereira</LastName>
<ForeName>Boscolli Barbosa</ForeName>
<Initials>BB</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-2633-9067</Identifier>
<AffiliationInfo><Affiliation>Institute of Geography, Department of Environmental Health, Federal University of Uberlândia, Santa Mônica Campus, Uberlândia, Brazil.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Institute of Biotechnology, Department of Genetics and Biochemistry, Federal University of Uberlândia, Umuarama Campus, Uberlândia, Brazil.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>12</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Toxicol Environ Health B Crit Rev</MedlineTA>
<NlmUniqueID>9802627</NlmUniqueID>
<ISSNLinking>1093-7404</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Toxicology</Keyword>
<Keyword MajorTopicYN="N">health care</Keyword>
<Keyword MajorTopicYN="N">public health</Keyword>
<Keyword MajorTopicYN="N">retinopathy</Keyword>
<Keyword MajorTopicYN="N">screening</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32281481</ArticleId>
<ArticleId IdType="doi">10.1080/10937404.2020.1752340</ArticleId>
<ArticleId IdType="pmc">PMC7157945</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Can J Cardiol. 2014 Dec;30(12):1706-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25475472</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Drug Des Devel Ther. 2018 Jun 11;12:1685-1695</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29928112</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Med Res Opin. 2015 May;31(5):1009-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25734693</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Toxicol Environ Health B Crit Rev. 2020;23(1):27-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31746269</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Dermatol Ther. 2007 Jul-Aug;20(4):160-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17970883</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Rheumatol. 2018 Dec;14(12):693-703</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30401979</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Ophthalmology. 2016 Jun;123(6):1386-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26992838</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Drug Investig. 2018 Aug;38(8):653-671</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29737455</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Joint Bone Spine. 2019 Jan;86(1):13-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30243782</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Ophthalmology. 2003 Jul;110(7):1321-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12867385</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Environ Mol Mutagen. 2001;38(1):69-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11473390</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28596841</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Drug Saf. 2018 Oct;41(10):919-931</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29858838</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Ophthalmology. 2015 Jan;122(1):110-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25182842</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hong Kong Med J. 2006 Aug;12(4):294-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16912357</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arthritis Care Res (Hoboken). 2010 Jun;62(6):775-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20535788</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Ophthalmology. 2002 Jul;109(7):1377-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12093666</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2020 Mar 5;177:104762</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arq Bras Oftalmol. 2019 Jan-Feb;82(1):12-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30403262</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Rheumatol. 2000 Dec;27(12):2927-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11128688</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Inflammopharmacology. 2015 Oct;23(5):231-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26246395</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>JAMA Ophthalmol. 2014 Dec;132(12):1453-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25275721</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-85-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25365095</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2020 Mar 26;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219882</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000207 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000207 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32281481
   |texte=   Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:32281481" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki